Tyra Biosciences FY Conference Summary Company Overview - **Company**: Tyra Biosciences (NasdaqGS:TYRA) - **Lead Drug**: Dabogratinib - **Focus**: Development of oral therapies targeting FGFR3-driven conditions Key Points Industry and Market Opportunity - Tyra is pursuing three potential blockbuster indications for dabogratinib, including: - **Upper Tract Urothelial Carcinoma (UTUC)**: High unmet need with a rapid registrational path [2][3] - **Non-Muscle Invasive Bladder Cancer (NMIBC)**: Targeting intermediate-risk patients with a focus on FGFR3-driven lesions [3][4] - **Achondroplasia**: Aiming to provide a significant height benefit through oral administration [4][42] Clinical Development Strategy - **Dabo 3x3 Strategy**: Focused on advancing dabogratinib into pivotal studies for the three indications [2] - **Phase 2 Data**: Expected mid-year for NMIBC, which will inform the design of a Phase 3 study [3][10] - **Safety and Efficacy**: Initial safety data from 22 patients showed a tolerable profile with low adverse events [14][15] Competitive Advantage - Tyra is the only company pursuing an oral option for these conditions, contrasting with current intravesical and surgical treatments [4][10] - The oral administration model is expected to enhance patient compliance and reduce the burden of treatment [26][28] Patient Journey and Adoption - The current standard of care involves invasive procedures, which patients and physicians are eager to replace with oral therapies [26][27] - Community practices are well-equipped to dispense oral medications, which could drive adoption of dabogratinib [27][29] Regulatory Pathway - The registrational path for UTUC is supported by previous FDA references to single-arm studies, allowing for a potentially expedited approval process [31][37] - Tyra plans to submit a briefing book to the FDA based on mid-year data to justify a Phase 3 design [16][37] Financial Projections - Tyra anticipates a significant market opportunity, projecting a billion-plus revenue potential for dabogratinib across all indications [39][55] - The company believes its internal projections exceed general analyst expectations, indicating strong future growth potential [55] Additional Insights - The company is focused on optimizing dosing strategies to enhance efficacy while maintaining safety [40][46] - There is a clear interest from the medical community in oral therapies, which could lead to favorable market dynamics for Tyra's products [28][30] Conclusion Tyra Biosciences is positioned to address significant unmet needs in oncology and rare diseases with its lead drug, dabogratinib. The company's strategic focus on oral therapies, combined with a robust clinical development plan and favorable market dynamics, suggests a strong potential for growth and success in the coming years.

Core Insights - Tyra Biosciences reported its financial results for Q4 and full-year 2025, highlighting its focus on developing precision medicines targeting FGFR biology, particularly through its "dabogratinib 3x3" strategy aimed at three potential blockbuster indications: LG-UTUC, IR NMIBC, and ACH [1][2] Financial Performance - The net loss for Q4 2025 was $33.8 million, an increase from $25.6 million in Q4 2024, while the full-year net loss was $119.9 million compared to $86.5 million in 2024 [2][3] - General and Administrative (G&A) expenses for Q4 2025 were $8.3 million, up from $7.6 million in Q4 2024, and for the full year, G&A expenses totaled $29.8 million compared to $24.1 million in 2024 [2][3] - Research and Development (R&D) expenses for Q4 2025 were $28.2 million, compared to $22.2 million in Q4 2024, with full-year R&D expenses reaching $102.9 million versus $80.1 million in 2024 [2][3] Cash Position - As of December 31, 2025, Tyra had cash, cash equivalents, and marketable securities totaling $256.0 million, which is expected to support operations through at least 2027 [2][3] Clinical Development - The "dabogratinib 3x3" strategy involves three pivotal clinical studies: - SURF302 for IR NMIBC, with initial three-month complete response data expected by the end of 1H 2026 [1][2] - BEACH301 for ACH, with interim results from the safety sentinel cohort anticipated in 2H 2026 [1][2] - SURF303 for LG-UTUC, with the first patient expected to be dosed in 2026 [1][2] Leadership Changes - In Q4 2025, Tyra strengthened its leadership team by appointing Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer, aimed at advancing clinical studies and preparing for future pivotal studies [1][2] Pipeline and Innovation - Tyra's lead candidate, dabogratinib, is an oral FGFR3-selective inhibitor currently in Phase 2 development for urologic cancers and skeletal dysplasias, with positive target engagement and safety results reported in over 100 patients [2][3] - The company continues to advance its SNÃ…P platform for precision medicine discovery, which aids in developing therapies for targeted oncology and genetically defined conditions [2][3]

Tyra Biosciences FY Conference Summary Company Overview - **Company**: Tyra Biosciences (NasdaqGS:TYRA) - **Focus**: Development of dabogratinib, an FGFR3 inhibitor for various indications including bladder cancer and skeletal dysplasias Key Points Drug Development and Indications - **Dabogratinib** is being explored for multiple uses, initially in metastatic bladder cancer and now expanding to earlier-stage bladder cancer and bone growth disorders like achondroplasia [3][4] - The drug targets **FGFR3** alterations, which are prevalent in specific cancer types and skeletal dysplasias [4] - Tyra is focusing on high-value opportunities with strong validation, particularly in low-grade upper tract urothelial carcinoma and intermediate-risk non-muscle invasive bladder cancer [4] Clinical Data and Safety - Tyra has conducted a Phase I trial demonstrating significant reduction in FGFR1 and FGFR2-associated toxicities, with a favorable safety profile compared to existing treatments [5][11] - Over 100 patients have been dosed, with ongoing studies to ensure safety and efficacy [11][12] - The drug has shown a favorable toxicity profile, with low-grade diarrhea being the most common side effect, which is manageable [15][16] Efficacy Expectations - Tyra anticipates improved efficacy in achondroplasia, aiming for additional growth benefits beyond current treatments [10][21] - The company is testing various doses (10, 20, 30, and 40 mg) to optimize growth outcomes while minimizing risks [29][31] - The expected outcomes for achondroplasia include significant height increases, with a target of achieving growth rates comparable to existing therapies [21][24] Bladder Cancer Focus - Tyra is prioritizing intermediate-risk non-muscle invasive bladder cancer due to the high prevalence of FGFR3 positivity (over 70%) in this group, which is crucial for treatment efficacy [42][47] - The company aims to reduce the need for invasive TURBT procedures, which are costly and burdensome for patients [50][63] - Tyra's oral therapy could significantly lower recurrence rates and improve patient quality of life compared to current treatment options [69][70] Future Trials and Pipeline - Tyra has multiple ongoing trials, including SURF301, SURF302, SURF303, and BEACH301, with data expected in the second half of the year for achondroplasia and mid-year for non-muscle invasive bladder cancer [87][88] - The company is also exploring new indications for FGFR3 and maintaining an active discovery program for additional therapeutic options [89] Market Potential - The unmet need in conditions like UTUC (upper tract urothelial carcinoma) is significant, with an estimated 40% of patients potentially losing their kidneys due to ineffective treatments [79][81] - Tyra's oral treatment could provide a compelling alternative, potentially leading to a market opportunity similar to that of Gleevec as the patient population grows [84] Conclusion - Tyra Biosciences is positioned to make significant advancements in the treatment of bladder cancer and skeletal dysplasias with its FGFR3 inhibitor, dabogratinib, focusing on safety, efficacy, and patient quality of life while addressing substantial unmet medical needs in these areas [90]

Core Insights - Tyra Biosciences, Inc. announced the acceptance of two abstracts for presentation at the 2026 ASCO Genitourinary Cancers Symposium, highlighting its focus on FGFR biology and precision medicine development [1] Group 1: Presentation Details - The first presentation is titled "ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial," scheduled for February 27, 2026, from 11:30 AM to 12:45 PM PST [1] - The second presentation is a phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302), also on February 27, 2026, from 11:30 AM to 12:45 PM PST [1] Group 2: Company Overview - Tyra Biosciences is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting FGFR biology, with a proprietary platform called SNÃ…P for rapid drug design [1] - The company has a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions, including oral dabogratinib, a potential first-in-class selective FGFR3 inhibitor [1] - Current planned clinical development includes three Phase 2 studies: SURF303 for low-grade upper tract urothelial carcinoma, SURF302 for intermediate risk non-muscle invasive bladder cancer, and BEACH301 for pediatric achondroplasia [1]

Core Viewpoint - Wedbush analyst Robert Driscoll has raised the price target for Tyra Biosciences (TYRA) to $53 from $37 while maintaining an Outperform rating on the shares, indicating a positive outlook for the company based on recent developments in the industry [1]. Group 1: Company Analysis - The price target for Tyra Biosciences (TYRA) has been increased to $53 from $37, reflecting a bullish sentiment from Wedbush [1]. - The firm maintains an Outperform rating on Tyra Biosciences, suggesting confidence in the company's future performance [1]. Group 2: Industry Insights - BridgeBio (BBIO) announced positive topline Phase 3 data for infigratinib in achondroplasia, which validates FGFR3 inhibition as an effective mechanism for increasing height velocity in patients with skeletal dysplasia [1]. - The positive data from BridgeBio is seen as encouraging for dabogratinib, a more selective FGFR3 inhibitor, which is expected to show significant increases in absolute annual height velocity (AHV) and potentially lead to clinically important changes in proportionality [1].

Summary of Key Points from Biotechnology Equity Research Conference Call Industry Overview - The report focuses on the biotechnology sector, specifically highlighting companies with significant potential for growth and upcoming catalysts in 2026. Key Companies and Their Outlook 1. **Dianthus Therapeutics, Inc. (DNTH)** - Market Cap: $1.82 billion - Price Target: $66 - Key catalysts include: - CIDP Phase III interim analysis in Q2 2026 - Initiation of gMG Phase III study in mid-2026 - Phase II MMN topline data in 2H26 - Potential for significant upside based on peak revenue estimates of ~$2 billion across neuromuscular diseases [19][20][24] 2. **Taysha Gene Therapies, Inc. (TSHA)** - Market Cap: $1.50 billion - Price Target: $11 - Focus on pivotal study for TSHA-102 in Rett syndrome with potential for a 6-month interim readout by YE26/1Q27 [26][27] 3. **Tyra Biosciences (TYRA)** - Market Cap: $1.36 billion - Price Target: $32 - Major catalysts include: - Phase III data for achondroplasia in early 2026 - Initial data for IR-NMIBC in 1H26 - Potential to disrupt the market with oral FGFR3 inhibitors [31][35] 4. **Tango Therapeutics, Inc. (TNGX)** - Market Cap: $1.15 billion - Price Target: $14 - Expected to show de-risking data for vopimetostat in combination with RVMD's RAS inhibitors in 2026 [37][40] 5. **ORIC Pharmaceuticals (ORIC)** - Market Cap: $783 million - Price Target: $23 - Key catalysts include dose-optimization data for prostate cancer and validating data from PFE's MEVPRO-1 trial [42][48] 6. **Solid Biosciences (SLDB)** - Market Cap: $463 million - Price Target: $15 - Focus on DMD program with key regulatory feedback expected in 1H26 [49][53] Major Catalysts and Events - **Upcoming Catalysts:** - RARE and MREO Phase III ORBIT final analysis expected in Dec'25/Jan'26 with potential stock movements of +100%/-30% [2] - ALNY, CRSP, and others expected to provide revenue guidance and business plans early in 2026 [1] - Regulatory events including FDA's Rare Disease Day on 2/23/26 [12] - **Drug Launches:** - Expected launches in 2026 include drugs from ALNY, ARWR, KALV, and others targeting various conditions [3] Financial Updates - **Price Target Changes:** - ARWR raised from $67 to $90 - KOD raised from $24 to $39 [6][10] Market Dynamics - **Pricing Stability:** - 2026 net pricing expected to remain stable with current Medicare contracts influencing high gross-to-net (GTN) guidance [12] - **Strategic Interest:** - Potential for M&A activity as companies like ORIC attract interest due to their prostate cancer programs [43] Conclusion - The biotechnology sector is poised for significant developments in 2026, with multiple companies presenting strong investment opportunities based on upcoming catalysts, drug launches, and strategic positioning in the market.

Tyra Biosciences Conference Call Summary Company Overview - **Company**: Tyra Biosciences (NasdaqGS:TYRA) - **Focus**: Precision small molecule medicine, specifically targeting FGFR3 with their lead drug, dabogratinib [2][4] Key Points and Arguments Drug Development and Clinical Trials - **Dabogratinib**: An FGFR3 selective inhibitor recently cleared for a phase two study in upper tract urothelial carcinoma, with ongoing trials for intermediate risk NMIBC and achondroplasia [2][3] - **Market Opportunity**: The FGFR3 positive bladder cancer market is estimated to be over $5 billion, with a significant unmet need in patients, particularly in the intermediate risk NMIBC setting [3][4] - **Efficacy Data**: Erdafitinib, a competitor, has shown a 35.3% overall response rate (ORR) at 8-9 mg dose, while a lower dose in the NMIBC setting yielded an 89% complete response (CR) rate [5][6] Competitive Landscape - **Unique Position**: Tyra is the only company advancing an FGFR3 selective oral drug, which is expected to have a better safety profile compared to existing treatments that affect FGFR1, 2, and 4 [4][6] - **Safety Profile**: Dabogratinib demonstrated significantly reduced toxicity compared to erdafitinib, with lower rates of common side effects such as nail disorders and hyperphosphatemia [6][8] Market Dynamics - **Urologist Engagement**: There is strong enthusiasm among urologists for oral therapies, as they can enhance practice revenue through in-office dispensing, similar to oral prostate cancer drugs [10][11] - **Switch Market Potential**: The treatment landscape is expected to shift towards oral options, with urologists likely to prefer oral therapies for recurrent patients rather than invasive procedures [29][30] Achondroplasia Program - **Growth Impact**: FGFR3 inhibition has shown potential to improve annualized height velocity (AHV) in children with achondroplasia, with Tyra aiming to exceed the 6 cm/year benefit seen in competitors [15][18] - **Preclinical Validation**: Studies indicate that targeting FGFR3 can lead to significant growth without severe toxicity, suggesting a favorable therapeutic window [17][19] Future Milestones - **Data Readouts**: Tyra expects to provide data on NMIBC and achondroplasia in 2026, with a well-financed position into 2028, holding $275 million [24] - **Regulatory Path**: Positive data could lead to a rapid transition to registrational studies, similar to competitors' paths [32][33] Additional Important Insights - **Unmet Needs in Upper Tract Urothelial Carcinoma**: This area presents a high burden of unmet need, with a significant percentage of patients being FGFR3 positive [12][13] - **Community Engagement**: There is a strong interest from the medical community in Tyra's studies, indicating a robust pipeline and potential for successful patient recruitment [21][23] This summary encapsulates the critical aspects of Tyra Biosciences' conference call, highlighting the company's strategic focus, competitive advantages, and future opportunities in the biotech landscape.

Core Insights - Tyra Biosciences is advancing its clinical programs, particularly focusing on dabogratinib for treating conditions like pediatric achondroplasia and bladder cancer, with interim results expected in 2026 [1][2][8] Clinical Development - The company has dosed the first patients in its Phase 2 studies, BEACH301 and SURF302, with expectations for interim results in 2026 [1][2] - Dabogratinib is being expanded into low-grade upper tract urothelial carcinoma (LG-UTUC), where FGFR3 alterations are present in approximately 85% of cases, with an IND cleared by the FDA [1][4][8] - The BEACH301 study is evaluating dabogratinib in children aged 3 to 10 with achondroplasia, while SURF302 focuses on FGFR3-altered low-grade intermediate risk non-muscle invasive bladder cancer [4][10] Financial Overview - As of September 30, 2025, Tyra Biosciences reported cash, cash equivalents, and marketable securities totaling $274.9 million, providing a runway through at least 2027 [1][10] - Research and development expenses for Q3 2025 were $25.5 million, an increase from $22.7 million in Q3 2024, primarily due to start-up and enrollment activities [10][19] - The net loss for Q3 2025 was $29.9 million, compared to $24.0 million for the same period in 2024 [10][19] Pipeline and Future Plans - The company is also developing TYRA-430, an FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, and TYRA-200, an FGFR1/2/3 inhibitor for advanced intrahepatic cholangiocarcinoma [4][12][14] - Upcoming milestones include initial results from the safety sentinel cohort of BEACH301 in 2H 2026 and initial three-month complete response data from SURF302 in 1H 2026 [10][11]

Tyra Biosciences (TYRA) Conference Summary Company Overview - **Company**: Tyra Biosciences (TYRA) - **Focus**: Discovery and development of selective FGFR3 inhibitors for cancer and achondroplasia treatment - **Key Products**: Lead compound is an FGFR3 selective inhibitor, dabogratinib (formerly TYR3-100) Pipeline Initiatives - **Active Phase II Trials**: - **Bladder Cancer**: Targeting intermediate risk FGFR3 positive non-muscle invasive bladder cancer (NMIBC) with a patient population of approximately 700,000 in the US, where FGFR3 positivity is 70-80% [5][11] - **Achondroplasia**: Addressing skeletal dysplasia caused by FGFR3 alterations, which leads to significant health complications [6][11] Study Design and Efficacy - **NMIBC Study**: - Phase II study randomizing patients to receive either 50 mg or 60 mg of dabogratinib daily [12] - Primary endpoint: 3-month complete response (CR) rate; secondary endpoints include duration of response and time to recurrence [12] - Anticipated CR rate benchmark is around 70% based on expert feedback [26] - **Achondroplasia Study**: - Initiated with a focus on pediatric dosing, starting at 0.125 to 0.5 mg/kg [73] - Emphasis on FGFR3 selectivity to optimize growth and reduce complications associated with the condition [78][86] Safety and Tolerability - **Dabogratinib Safety Profile**: - Demonstrated a pristine safety profile with low-grade adverse events (AEs) such as diarrhea and asymptomatic ALT/AST elevations [19][40] - No hyperphosphatemia observed at doses of 50-60 mg, contrasting with other pan FGFR inhibitors [40][64] Competitive Landscape - **Comparison with Other Treatments**: - Dabogratinib shows a significantly improved safety profile compared to erdafitinib, with lower rates of nail toxicity and stomatitis [63] - The oral administration of dabogratinib is expected to enhance patient adherence compared to intravesical therapies [50][51] Market Dynamics - **Community Channel Dynamics**: - The evolution of oral therapies in urology, supported by EuroGPO, has facilitated the adoption of oral drugs in community practices [55][58] - Oral drug spend in urology has reportedly increased from 5% to 15% since 2008, with indications that it may be as high as 40% today [57] Future Outlook - **Prioritization of Trials**: - The company is focusing on the intermediate risk NMIBC and achondroplasia settings due to larger patient populations and unmet needs [70][72] - Future discussions with the FDA regarding the metastatic urothelial carcinoma setting are planned, but current focus remains on ongoing Phase II trials [69][72] Key Takeaways - Tyra Biosciences is advancing innovative treatments for bladder cancer and achondroplasia with a strong emphasis on safety and patient convenience - The company is well-positioned in the market with a promising pipeline and a clear strategy for commercialization and patient engagement - Ongoing studies are expected to provide critical data that will shape the future of treatment options in these therapeutic areas [21][72]

Core Insights - Tyra Biosciences has initiated the BEACH301 Phase 2 clinical study for dabogratinib, the only oral FGFR3-selective inhibitor in development for achondroplasia, marking a significant milestone in the treatment of this condition [1][2][3] Company Overview - Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines targeting FGFR biology, utilizing its in-house SNÅP platform for drug design [9] - Dabogratinib is the lead candidate from Tyra's pipeline, designed to be a first-in-class oral FGFR3-selective inhibitor, with ongoing clinical trials for both pediatric achondroplasia and cancer [7][9] Clinical Study Details - The BEACH301 study will evaluate dabogratinib in children aged 3 to 10 with achondroplasia, enrolling treatment-naïve participants and those who have received prior therapies [4][5] - The study aims to assess safety, tolerability, and growth velocity changes, with a focus on improving the quality of life for children with achondroplasia [5][6] Market Context - Achondroplasia affects approximately 1 in 15,000 to 40,000 children, with around 250,000 individuals impacted globally, highlighting a significant unmet medical need [2][6] - The FGFR3 G380R mutation is responsible for about 99% of achondroplasia cases, indicating a targeted therapeutic approach could be beneficial [2][6]